Serum metabolite concentrations provide a direct readout of biological processes in the human body, and they are associated with disorders such as cardiovascular and metabolic diseases. We present a genome-wide association study (GWAS) of 163 metabolic traits measured in human blood from 1,809 participants from the KORA population, with replication in 422 participants of the TwinsUK cohort. For eight out of nine replicated loci (FADS1, ELOVL2, ACADS, ACADM, ACADL, SPTLC3, ETFDH and SLC16A9), the genetic variant is located in or near genes encoding enzymes or solute carriers whose functions match the associating metabolic traits. In our study, the use of metabolite concentration ratios as proxies for enzymatic reaction rates reduced the variance and yielded robust statistical associations with P values ranging from 3 × 10 −24 to 6.5 × 10 −179 . These loci explained 5.6%-36.3% of the observed variance in metabolite concentrations. For several loci, associations with clinically relevant parameters have been reported previously.
Serum metabolite concentrations provide a direct readout of biological processes in the human body, and they are associated with disorders such as cardiovascular and metabolic diseases. We present a genome-wide association study (GWAS) of 163 metabolic traits measured in human blood from 1,809 participants from the KORA population, with replication in 422 participants of the TwinsUK cohort. For eight out of nine replicated loci (FADS1, ELOVL2, ACADS, ACADM, ACADL, SPTLC3, ETFDH and SLC16A9), the genetic variant is located in or near genes encoding enzymes or solute carriers whose functions match the associating metabolic traits. In our study, the use of metabolite concentration ratios as proxies for enzymatic reaction rates reduced the variance and yielded robust statistical associations with P values ranging from 3 × 10 −24 to 6.5 × 10 −179 . These loci explained 5.6%-36.3% of the observed variance in metabolite concentrations. For several loci, associations with clinically relevant parameters have been reported previously.
We have previously identified frequent genetic polymorphisms with large effects that alter an individual's metabolic capacities 1 . In that study we described genetic variants in metabolism-related genes that lead to specific and clearly differentiated metabolic phenotypes, which we call 'genetically determined metabotypes'. Knowledge of these genetically determined metabotypes in human populations is central to identifying the contributions and interactions of genetic and environmental factors in the etiology of complex diseases, providing a new paradigm for the study of gene-environment interactions. However, our original GWAS was limited in power because of its modest number of participants (n = 284). In an effort to identify new major genetically determined metabotypes of biomedical relevance, we conducted a GWAS to metabolic traits in human serum using cohorts of larger sample sizes.
We genotyped KORA samples using the Affymetrix 6.0 GeneChip array and TwinsUK samples using the Illumina Hap317K chip. We also determined fasting serum concentrations of 163 metabolites, covering a biologically relevant panel of amino acids, sugars, acylcarnitines and phospholipids, using electrospray ionization tandem mass spectrometry (ESI-MS/MS) with the Biocrates AbsoluteIDQ targeted metabolomics technology. A full list of the measured metabolites, the abbreviations used to denote them in this paper, and their biological roles is presented in the Online Methods section. Motivated by our previous finding that use of metabolite concentration ratios as proxies for enzymatic reaction rates reduces the variance and yields robust statistical associations 1,2 , we tested all of the 163 metabolite concentrations and also all possible metabolite concentration ratios (163 × 162 = 26,406 traits) with a linear additive model for association with all single-nucleotide polymorphisms (SNPs) that passed our selection criteria. The corresponding estimated genome-wide significance level after correction for testing 517,480 SNPs (minor allele frequency (MAF) > 10%) and 26,406 multiple metabolic trait combinations is P = 3.64 × 10 −12 (see Online Methods). This hypothesis-free approach highlights pairs of metabolites that are more likely to be coupled either biochemically or physiologically.
We applied a two-step discovery design in the KORA F4 population, followed by a replication step in the TwinsUK cohort. Starting with an initial discovery step based on samples of 1,029 male and female individuals of Southern German origin from the KORA F4 population, we selected all loci with P values of association <10 −7 for metabolite concentrations and P < 10 −9 for concentration ratios in a GWAS (Fig. 1) volume 42 | number 2 | february 2010 Nature GeNetics l e t t e r s 32 loci satisfied these criteria. We then tested one SNP for each locus in a second step in an independent sample of 780 participants selected from the remaining KORA F4 population, using identical genotyping and metabolomics techniques as in the first step. The metabolomics and genotyping experiments for this second step were conducted independently and after completion of the initial study, with an interval of several months. Using data from all 1,809 individuals from the KORA group, we computed joint P values of association. Although this approach is less well powered than a full genome-wide joint analysis, it reflects the historical way in which we selected SNPs for follow-up. The top P values from the discovery step are presented in Supplementary Table 1 , and a full list is available on request.
We identified 15 loci for which the strength of association increased when additional data were added, and we selected only those for further investigation. All 15 loci had genome-wide significant P values of association that were smaller than 3.64 × 10 −12 in this joint analysis ( Table 1 ; local association plots, box plots by genotype and quantilequantile plots are presented in Supplementary Figs. 1−3) . In a third step, for replication in an independent population, we used metabolomics data, measured on our platform, from serum samples of 422 female participants of the TwinsUK cohort. Of the 15 loci tested, 9 were replicated (P < 0.05) after Bonferroni correction for 15 tests. Five loci showed signals of association with similar effect-size estimates, but their significance was measured above our threshold, and thus they should be considered as unreplicated. However, this suggestive evidence of an association is supported for four of those five loci (CPS1, SCD, SLC22A4 and PHGDH) by biological evidence, and two of them (CPS1 and SLC22A4) represent indirect replications of previous studies (Supplementary Note). Note also that the TwinsUK study had only limited power because of its smaller sample size. Moreover, all SNPs but one were imputed, and the signal-to-noise ratio in the TwinsUK metabolomics data was about 20% higher than that in the KORA data.
When the functional roles of the genes in these loci are considered, we can draw the most comprehensive view to date of genetic variation in human metabolism. The connections between these genes in the human metabolism are outlined in Figure 2 . For eight of nine fully replicated genetic polymorphisms, and also for four of the five suggestive loci, the genetic variant is located in or near enzyme-encoding or solute carrier−encoding genes for which the associating metabolic traits match the proteins' function. Many of these polymorphisms affect proteins involved in rate-limiting steps of important enzymatic reactions. Four loci (FADS1, ACADS, ACADM and ELOVL2) replicate associations from previous studies, including our own. Two of the suggestive loci (SLC22A4 and CPS1) replicate previous studies on related metabolic traits. For some loci (for example, SLC16A9 and PLEKHH1), new hypotheses on the genes' function can be derived from the associating metabolite pattern. For three loci, an association with clinical end points has previously been reported (SLC22A4 with Crohn's disease, FADS1 with hyperactivity and cholesterol and triglyceride levels and ACADS as a susceptibility locus for ethylmalonic aciduria).
For several other loci (for example, ACADM, ACADL and ETFDH), loss of function of the corresponding gene leads to severe disorders, indicating that the genetic variants we identify here, or variants in linkage disequilibrium, may induce a related but probably more moderate phenotype. This is in line with findings of a recent GWAS on kidney function that identified UMOD to be associated with glomerular filtration rate 3 . Rare mutations in the UMOD gene are known to be the cause of monogenic autosomal dominant kidney diseases. Common mutations in the same gene region can be the cause of disease-related phenotypes of less severity on the population level. As discussed previously 1 , a ratio between the concentrations of two metabolites that are linked to a substrate-product pair of some enzymatic reaction may constitute an approximation of the conversion rate of that reaction. From the effect size of the association (b′ in the linear model), one can therefore derive the per-allele difference in metabolic capacities of an individual with respect to the enzymatic reaction considered. For instance, b′ of the association of rs211718 (ACADM) with C12/C10 is 0.12. Assuming an additive-per-copy effect (Supplementary Fig. 2 ), this implies that individuals who are homozygotes of the major allele of ACADM burn fatty acids with a chain length of 12 carbons about 24% faster than do carriers of two copies of the minor allele. Similar arguments hold for the other loci (b′ for all loci is reported in Supplementary Table 2 ).
The SNPs identified in this study can now be examined in GWAS with clinical parameters. As an example, in our previous study 1 we suggested FADS1 to be a risk locus for perturbed blood lipid parameters. This was supported by the observed association with different phospholipids and the fact that two published GWAS investigating lipid levels reported P values of association for the FADS1 locus with levels of low-density lipoprotein (LDL), high-density lipoprotein (HDL) and total cholesterol that ranged between 1.89 × 10 −4 and 6.07 × 10 −5 (refs. 4,5) . These associations had not been included in the list of potential candidates for replication in those studies, as their P values taken alone were not sufficiently small in the context of a classical GWAS. Three better-powered GWAS with lipid parameters have only recently confirmed this prediction [6] [7] [8] , thereby proving that a combination of a GWAS using metabolomic phenotypic traits with data from previous GWAS can identify new candidate SNPs associated with known phenotypes of clinical relevance. To facilitate further 
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Association with concentration ratios Figure 1 Manhattan plot of the strength of association with metabolite concentrations (above, data points with P < 10 −7 are plotted in red) and concentration ratios (below, data points with P < 10 −9 are plotted in red), based on association with 1,029 samples (step 1 of discovery stage). For each SNP, only the metabolic trait with the lowest P value of association is shown; thus, multiple dots indicate that several SNPs support the association at that locus.
l e t t e r s studies, we provide a list of all high-scoring associations of this study to allow similar use by other consortia (Supplementary Table 1 ).
The association data presented in this study can be used to learn more about previously reported associations to related traits. Using the Catalog of Published Genome-Wide Association Studies (ref. 9, see URLs; accessed 14 April 2009), we identified three such loci that also associate with metabolic traits in our study ( Table 2) . For instance, SNP rs964184 in the apolipoprotein cluster APOA1-APOC3-APOA4-APOA5 associates strongly with blood triglyceride levels (P < 10 −60 ) 4 . We find that the same SNP associates with ratios between different phosphatidylcholines (for example, PC aa C36:2/PC aa 38:1 (see Online Methods for an explanation of metabolite denotation); P = 1.8 × 10 −10 ), which are biochemically connected to triglycerides by the intermediary of only a few enzymatic reaction steps. SNP rs1260326 (a polymorphism resulting in a P446L substitution) in GCKR, which encodes the glucose kinase regulator protein, inversely modulates fasting glucose (P = 8 × 10 −13 ) and triglyceride levels (P = 1 × 10 −4 ) and reduces type 2 diabetes risk in the DESIR prospective general French population 10 . This locus associates with different ratios between plasmalogens and phosphatidylcholines (for example, l e t t e r s PC ae C34:2/PC aa C32:2; P = 3.2 × 10 −8 ), thereby providing new avenues for further investigation of the functional background of this association. SNP rs10830963 in the gene encoding melatonin receptor (MTNR1B) associates with fasting glucose 11 . The same SNP associates in this study with tryptophan/phenylalanine ratios (P = 5.7 × 10 −6 ). This is notable because phenylalanine is a precursor of melatonin, indicating a functional relationship between this pathway and the regulation of glucose homeostasis. We expect the list of loci with parallel association of clinically relevant parameters and metabolic traits to grow as new GWAS become available, and we therefore provide our association data for such use (Supplementary Table 1 ).
The SNPs identified in this study can also be used in clinical studies for association with response to drug treatment. One published example is a common polymorphism in the gene encoding dihydropyrimidine dehydrogenase (DPYP) that associates strongly with fluoropyrimidine-related toxicity in cancer patients 12 . Carriers of this variant could benefit from individual dose adjustment of the fluoropyrimidine drug or from alternative therapies. It is now possible to use the here-identified SNPs in association studies with phenotypes that are specific to a disease, such as the development of particular complications during the course of a disease or treatment. One published example is a SNP in the gene encoding carnitine palmitoyltransferase II (CPT-II) that is a predisposing factor for influenza-associated encephalopathy (thermolabile phenotype) 13 . Indeed, the SNP that we identified here in ACADL has been patented by others 14 , along with the CPT-II polymorphism, as a method of diagnosing the risk of a thermolabile phenotype.
In summary, this study allowed us to draw a systemic perspective of the genetic variation that is found in human metabolism. In contrast to most GWAS with clinically relevant end points, it seems that for metabolic traits most of the associations are linked to genetic variants in genes with a matching metabolic function (Fig. 2) . The use of metabolite concentration ratios results in a pronounced sharpening of the association with strongly decreased P values when compared to an analysis of single metabolites. Moreover, as we show with examples (FADS1, the APO cluster, MTNR1B and GCKR), it allows for comparisons to GWAS with clinically relevant end points. Our study demonstrates the exciting potential of metabolomics to unravel the genetics of human metabolism. The genome-wide perspective on genetic variation in human metabolism presented here will continue to improve as more extensive metabolite panels become available for use on a genome-wide scale, with, among others, additional studies that include nutritional challenges of the participants. We believe that the introduction of metabolomics into the field of molecular epidemiology provides a new hypothesis-driven approach to GWAS.
MeThOdS
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Note: Supplementary information is available on the Nature Genetics website. ONLINe MeThOdS No evidence of population stratification has been found in multiple published analyses using the KORA cohort.
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Genotyping and imputation. In KORA F4, we carried out genotyping using the Affymetrix 6.0 GeneChip array. Analysis in the discovery stage was performed solely on genotyped SNPs. As is current standard for GWAS, we excluded all X chromosome−linked SNPs for the following reasons: (i) the X chromosome must be treated differently from the autosomes; (ii) it cannot be predicted which allele is active; (iii) testing males separately results in different sample sizes and power. Imputation of SNPs in the HapMap CEU population was performed using IMPUTE 16 for use in the regional association plots. In the discovery stage we limited our analysis to SNPs with a moderate-to-high MAF (>10%) and a high genotyping quality (call rate >95%) and with respect to Hardy-Weinberg equilibrium (P HWE > 0.001). A total of 517,480 SNPs satisfied all of these criteria.
Blood sampling. We collected blood samples for metabolic analysis between 2006 and 2008 in parallel with the KORA F4 examinations. To avoid variation due to circadian rhythm, blood was drawn in the morning between 8:00 a.m. and 10:00 a.m. after a period of overnight fasting. Material was drawn into serum gel tubes, gently inverted two times and then allowed to rest for 30 min at room temperature (18−25 °C) to obtain complete coagulation. The material was then centrifuged for 10 min (2,750g at 15 °C). Serum was divided into aliquots and kept for a maximum of 6 h at 4 °C, after which it was deep frozen to −80 °C until analysis.
Metabolite measurements. Liquid handling of serum samples (100 µl) was performed with a Hamilton Star (Hamilton Bonaduz AG) robot, and samples were prepared for quantification using the AbsoluteIDQ kit (BIOCRATES Life Sciences AG). Sample analyses were done on API 4000 Q TRAP LC/MS/ MS System (Applied Biosystems) equipped with a Schimadzu Prominence LC20AD pump and a SIL-20AC autosampler. The complete analytical process was performed using the MetIQ software package, which is an integral part of the AbsoluteIDQ kit. We did not apply any data correction, nor did we remove any data points. To estimate whether deviation from normality of metabolite ratios may have biased our results, we tested associations for both untransformed and logscaled ratios; we detected no significant differences (Supplementary Table 3 ).
The reported P values of step 1 of the discovery stage were not corrected for genomic inflation, as the genomic control inflation factors λ are small, ranging from 1.00 to 1.03, both in KORA and in TwinsUK.
Replication in the TwinsUK study. The TwinsUK cohort is an adult twin British registry. These unselected twins were recruited from the general population through national media campaigns in the United Kingdom and were shown to be comparable to age-matched population singletons in terms of disease-related and lifestyle characteristics 22 . Ethics approval was obtained from the Guy's and St. Thomas' Hospital Ethics Committee. Written informed consent was obtained from every participant in the study. We genotyped a total of 2,277 individuals of European ancestry (1,073 singletons and 602 dizygotic twins) from the TwinsUK registry using the Illumina Hap317K chip. We applied a strict quality control at both individual and SNP levels. We excluded 51 individuals because of their non-European ancestry and 3,366 SNPs because of a MAF of <1%, a call rate of <95% if the MAF was <5% or a call rate of <99% if the MAF was >5%, or P HWE <1 × 10 −4 . After the quality control, 305,811 autosomal SNPs available from 2,226 individuals (1,046 singletons and 590 dizygotic twins) were available and used for imputation. The imputation was carried out using the IMPUTE software 16 . NCBI build 36 was used for strand reference. We have made available data for 2.5 million autosomal imputed from these 2,226 individuals. We selected 422 unrelated individuals from those genotyped for the metabolomics assay. For the TwinsUK study, blood samples were taken after at least 6 h of fasting. The samples were immediately inverted three times, followed by 40 min resting at 4 °C to obtain complete coagulation. The samples were then centrifuged for 10 min at 2,000g. Serum was removed from the centrifuged brown-topped tubes as the top, yellow, translucent layer of liquid. Four aliquots of 1.5 ml were placed into skirted microcentrifuge tubes and then stored in a −45 °C freezer until sampling. Metabolite measurements were performed using the same metabolomics platform and following an identical protocol as for the KORA study at the Genome Analysis Centre of the Helmholtz Zentrum München. For the purpose of the replication for the KORA study, the data on the metabolites, the
